# Chugai Venture Fund

> Chugai Venture Fund is a VC fund in Boston backing Biotechnology and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 7
- Last investment: Feb 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.chugaiventurefund.com/

Chugai Venture Fund is a pioneering investment firm that promotes innovation and creates revolutionary improvements in the life sciences industry.

## Contacts

5 contacts available for Chugai Venture Fund. Shizune tracks 2 team members at Chugai Venture Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/chugai-venture-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| SaaS | 1 | 14% |
| Health Care | 1 | 14% |
| Therapeutics | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Venture - Series Unknown | 2 | 29% |
| Debt Financing | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Gustofson | Founder & President | 10 | https://shizune.co/investors/profile/john-gustofson |
| Mike Dial | Managing Director | 7 | https://shizune.co/investors/profile/mike-dial-742c |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Dualitas Therapeutics | Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline | $65M | Series A | Sep 16, 2025 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $30M | Series A | Aug 27, 2025 |  |
| Stylus Medicine | Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders. The company is based in Cambridge, Massachusetts. | $85M | Series A | May 12, 2025 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. |  | Debt Financing | Oct 30, 2024 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $6M | Venture - Series Unknown | Oct 30, 2024 |  |

7 of 7 investments shown.

## Co-investors
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [Euclidean Capital](https://shizune.co/investors/profile/euclidean-capital) — VC Fund, 3 deals together
- [Newpath Management](https://shizune.co/investors/profile/newpath-management-l-p) — VC Fund, 3 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [PhiFund Ventures](https://shizune.co/investors/profile/phifund-ventures) — VC Fund, 3 deals together
- [Draper Associates](https://shizune.co/investors/profile/draper-associates-2) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chugai Venture Fund invest in?

Chugai Venture Fund invests primarily in Biotechnology, Medical and SaaS startups, most often at Series A and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Chugai Venture Fund?

Public channels for Chugai Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Chugai Venture Fund?

The team at Chugai Venture Fund includes John Gustofson (Founder & President) and Mike Dial (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co